
|Articles|February 20, 2006
New biologic helps those with PI help themselves
Until now, patients with primary immunodeficiency (PI) were treated with intravenous immunoglobulin (IVIg) infusions, which were inconvenient and associated with serious adverse side effects, such as migraine headaches.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
SGLT2is Significantly Benefit Kidney, Hospitalization, and Mortality Outcomes
2
Pharmacy Leaders Gather to Improve Electronic Prior Authorization
3
SGLT2is Lower CKD Risk Regardless of eGFR, Albuminuria
4
Obesity-Fertility Program Significantly Improved Women’s Lifestyle Behavior
5




















































































































































